Okogen, Inc.
Biotechnology ResearchTexas, United States2-10 Employees
Okogen, Inc., is a private biotechnology company focused on novel therapeutics to treat unmet need in ophthalmic infectious diseases.
Innovative Therapeutics Okogen is focused on developing novel therapeutics for ophthalmic infectious diseases, creating opportunities for partnerships in ophthalmology and infectious disease markets.
Strategic Expansion Relocation of headquarters to Plano, Texas, signals growth and potential expansion activities, making the company more accessible for local collaborations and investment.
Funding & Development With recent financing of $3.3 million supporting its Phase 2b clinical program for conjunctivitis, Okogen is in a growth phase that can attract further funding and clinical partnerships.
Regulatory Milestones Appointment of a new Chief Medical Officer and advancing clinical trials highlight the company’s focus on achieving regulatory milestones, ideal for strategic alliances or licensing opportunities.
Technology Integration Development of AI-powered evaluation tools indicates a potential for collaborations in digital health and medical AI solutions targeting ophthalmology and infectious disease diagnostics.
Okogen, Inc. uses 8 technology products and services including Usercentrics, Cloudflare, WordPress, and more. Explore Okogen, Inc.'s tech stack below.
| Okogen, Inc. Email Formats | Percentage |
| FLast@okogen.com | 50% |
| FLast@okogen.com | 50% |
Biotechnology ResearchTexas, United States2-10 Employees
Okogen, Inc., is a private biotechnology company focused on novel therapeutics to treat unmet need in ophthalmic infectious diseases.
Okogen, Inc. has raised a total of $3.3M of funding over 4 rounds. Their latest funding round was raised on Dec 11, 2024 in the amount of $3.3M.
Okogen, Inc.'s revenue is estimated to be in the range of $1M
Okogen, Inc. has raised a total of $3.3M of funding over 4 rounds. Their latest funding round was raised on Dec 11, 2024 in the amount of $3.3M.
Okogen, Inc.'s revenue is estimated to be in the range of $1M